Successful outcome of pharmacokinetic trial in children of lead candidate

Cessatech A/S announces positive topline outcome of its Phase 2 pharmacokinetics trial with CT001… Cessatech A/S announces positive topline outcome of its Phase 2 pharmacokinetics trial with CT001 in children, which met the primary endpoint of the trial. The trial was designed as a non-randomised, open-label study carried out in 25 children aged 1-17 years who needed premedication for placement of a peripheral venous catheter for general anaesthesia related to a surgical procedure 220923 – TopLine Results of trial 0206 Related articles Releases 27. August, 2026 CT001 ready for shipment to initial U.S. hospitals as launch activities commence Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with... Read more Releases 24. July, 2026 Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu See also the updated Q&A documentation related to the Release: Link The European Medicines... Read more Releases 12. June, 2026 Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children ... Read more Stay up to date! Subscribe and get notified on Cessatech's latest news. An acceptance email will be sent to you, please check your spam. Please leave this field empty Almost there! Please check your inbox to confirm your subscription to Cessatech.

The release as fetched from its publisher. cessatech.com ↗